| AZD8931, an Equipotent, Reversible Inhibitor of Signaling by Epidermal Growth Factor Receptor, ERBB2 (HER2), and ERBB3: A Unique Agent for Simultaneous ERBB Receptor Blockade … DM Hickinson, T Klinowska, G Speake, J Vincent, C Trigwell, J Anderton, ... Clinical Cancer Research 16 (4), 1159-69, 2010 | 141 | 2010 |
| Identification of Biomarkers in Human Head and Neck Tumor Cell Lines That Predict For In Vitro Sensitivity to Gefitinib DM Hickinson, GB Marshal, GJ Beran, M Varella-Garcia, EA Mills, ... Clinical Translational Science 2 (3), 183-92, 2009 | 54 | 2009 |
| Phase ia/b, open-label, multicenter study of AZD4635 (an adenosine A2A receptor antagonist) as monotherapy or combined with durvalumab, in patients with solid tumors EA Lim, JC Bendell, GS Falchook, TM Bauer, CG Drake, JH Choe, ... Clinical Cancer Research 28 (22), 4871-4884, 2022 | 43 | 2022 |
| Abstract CT007: PETRA: first in class, first in human trial of the next generation PARP1-selective inhibitor AZD5305 in patients (pts) with BRCA1/2, PALB2 or RAD51C/D mutations TA Yap, SA Im, AM Schram, A Sharp, J Balmana, RD Baird, JS Brown, ... American Association for Cancer Research (AACR), 2022 | 37 | 2022 |
| Can you trust your animal study data? IS Peers, MC South, PR Ceuppens, JD Bright, E Pilling Nature Reviews Drug Discovery 13 (7), 560-560, 2014 | 33 | 2014 |
| Enantiomeric pairs reveal that key medicinal chemistry parameters vary more than simple physical property based models can explain AG Leach, EA Pilling, AA Rabow, S Tomasi, N Asaad, NJ Buurma, ... MedChemComm 3 (5), 528-540, 2012 | 30 | 2012 |
| A phase I, open-label, multicenter study to assess the safety, pharmacokinetics, and preliminary antitumor activity of AZD4635 both as monotherapy and in combination in … EA Lim, TM Bauer, MR Patel, GS Falchook, JL Karlix, JH Choe, ... Journal of Clinical Oncology 38 (15_suppl), 5518-5518, 2020 | 22 | 2020 |
| Defining estimands for efficacy assessment in single arm phase 1b or phase 2 clinical trials in oncology early development S Englert, F Mercier, EA Pilling, V Homer, C Habermehl, S Zimmermann, ... Pharmaceutical Statistics 22 (5), 921-937, 2023 | 4 | 2023 |
| Multidisciplinary considerations for implementing Bayesian borrowing in basket trials KR Broglio, JE Blau, EA Pilling, JMS Wason Drug Discovery Today 29 (9), 2024 | | 2024 |
| Comprehensive clinical pharmacology characterization of AZD4635 in healthy participants to support dosing considerations G Moorthy, GP Pouliot, L Graham, E Pilling, L Jung, R Alcobi, Y Zhu, Y Li, ... British Journal of Clinical Pharmacology 89 (9), 2775-2787, 2023 | | 2023 |
| Can serum markers of bone metabolism predict the progression of knee OA? PA Berry, RA Maciewicz, FM Cicuttini, MD . Downey-Jones, EA Mills, ... Bone 44 (S1), S143, 2009 | | 2009 |
| Evaluation of AZD8931, an Equipotent Inhibitor of erbB1, erbB2, and erbB3 Receptor Signaling, on Ligand Stimulated Breast Cancer Cell Lines with Differing Levels of erbB2 … G Marshall, T Klinowska, E Mills, D Ogilvie, D Hickinson, G Speake Cancer Research 69 (24), 2009 | | 2009 |
| PREDICTIVE RELATIONSHIP OF SERUM MARKERS OF CARTILAGE METABOLISM TO IMAGING AND CLINICAL OUTCOME MEASURES OF JOINT INTEGRITY PA Berry, RA Maciewicz, AE Wluka, EA Downey-Jones, M.D., Mills, ... Osteoarthritis and Cartiladge 16 (S4), S58, 2008 | | 2008 |
| BLOOD TRANSCRIPTOMIC PROFILES CAN SEGMENT OSTEOARTHRITIS PATIENT POPULATIONS C Oakley, KL Limer, L Elston, S Roberts, EA Mills, M Doherty, ... Osteoarthritis and Cartiladge 15, C161, 0 | | |
